KPTI$0.0952-15.00%
Karyopharm Therapeutics Inc.
Sector: Pharmaceutical PreparationsIndustry: BiotechnologyCountry: USExchange: Nasdaq
Mkt Cap:$2.16M
Float & O/S:
Inst Own:
DilutionScan read 54 of Karyopharm Therapeutics Inc.'s SEC filings and found 9 warrant series, 5 convertibles, 1 ATM program, 6 shelf registrations and 7 completed offerings on file for KPTI. The latest dilution event on file is an offering on Sep 17, 2026. Analysis updated Nov 3, 2026.
Signal8 Summary
KPTI
Going-concern warning from auditors
Snapshot
Karyopharm is a commercial-stage biotech with a healthy product gross margin (96%) but a deeply strained balance sheet. The company generates roughly $146M in revenue, yet spends heavily on R&D and sales (158% of revenue combined), leading to a $196M net loss and a $75M annual cash burn.
What's Happening Right Now
- : The Phase 3 endometrial cancer trial missed its primary endpoint, and the company plans to reduce investment in that area to prioritize myelofibrosis and multiple myeloma programs.
- : Karyopharm plans to submit a supplemental New Drug Application in August 2026 for accelerated approval of selinexor plus ruxolitinib in myelofibrosis.
- : The company disclosed a going-concern warning in its Q1 2026 10-Q, stating there is substantial doubt it can continue operating within one year without raising additional capital.
